Dr. Angela Knierim

Angela is a member of the Practice Area Patents Technology & Life Sciences and the Industry Group Life Sciences & Healthcare. She advises national and international pharmaceutical and medical device companies on all aspects of health law.

One of her main areas of practice is litigation and dispute resolution of competition law complaints (enforcement and defence) in both drug advertising and medical device law. Another focus of her practice is the review of marketing materials and campaigns in terms of drug advertising law. In addition, she provides regulatory advice with regard to the manufacture, labelling and marketing of medicinal products, medical devices, dietary supplements, cosmetics, biocides and chemicals. Angela is member of the Israel Group.

Show full CV Hide full CV

Career

Since 2022	Salary Partner, Taylor Wessing
2020	Senior Associate, Taylor Wessing
2019 – 2020	Associate, Taylor Wessing

2020	Lecturer for Regulatory Affairs/Digital Health Management, Aalen University
2017 – 2019	Associate, a law firm specialized in Life Sciences & Healthcare, Duesseldorf

More Show less

Education

2017	Ph.D., University of Heidelberg
2017	Admitted to the Bar
2016	Second Bar Examination, Higher Regional Court of Duesseldorf

2014 – 2016	Legal clerkship, Regional Court of Duesseldorf, a.o. with station in Sydney, Australia
2014	Scientific Assistant at a law firm specialized in medical criminal law and white collar crime, Duesseldorf
2012	First Bar Examination, University of Heidelberg
2006 – 2012	Legal studies, University of Heidelberg

More Show less

Publications

Aktuelle Rechtsfragen zu Therapieallergenen, in: PharmR, 12/2012, gemeinsam mit Daniel Tietjen

Angaben „schnell“ und „nachhaltig“ sind keine vergleichende Werbung – Anm. zu OLG Hamburg, Urteil vom 17.12.2020 – 3 U 199/19, in: GRUR-Prax 2021, S. 458

Health Apps auf Rezept - Start für digitale Gesundheitsanwendungen, in: Medizinprodukte Journal, 03/2020, S. 207 (gemeinsam mit Dr. Nicolai Wiegand)

Patents and approvals – medicines, vaccines and diagnostics for COVID-19, in: European Pharmaceutical Review, 03/2020, p. 24 (with Paul England, Dr. Anja Lunze, Jan Phillip Rektorschek and Alison Dennis)

Pharmaceutical Patent Law in Times of Crisis: A Comparative Study Part II, in: European Intellectual Property Review Volume 42, Issue 10, 2020, p. 643 (with David Mulder, Christian Dekoninck, Adrian Toutoungi, Matthew Caskie, Dr. Anja Lunze, Barbora Dubanská und Dr. Agnieszka Sztoldman)

Die Erstattungsfähigkeit von Therapieallergenen im Zulassungsverfahren, in: PharmR, 02/2020, S. 61

Kommentierung der §§ 25b, 25c, 37, 83, 83a AMG (gemeinsam mit Dr. Alexander Natz), in: Zuck/Dettling (Hrsg.), Arzneimittelgesetz, 2020

Anmerkung zum Urteil des Bundessozialgerichts vom 30. November 2017, Az.: B 3 KR 3/16 R und zum Urteil des Landessozialgerichts Berlin-Brandenburg vom 22. Februar 2018, Az.: L 1 KR 56/14, in MPR 01/2019

Dissertation: Das Tatbestandsmerkmal „Verlangen“ im Strafrecht. Zugleich ein Beitrag zur Unrechtslehre am Beispiel der Tötung auf Verlangen und des Schwangerschaftsabbruchs nach Konfliktberatung, Duncker & Humblot 06/2018:

Kooperation von Versandapotheke mit Internetplattform ist unzulässig – Anm. zu OLG Köln, Urt. v. 22.02.2017 – 6 U 101/16 (gemeinsam mit Dr. Christian Stallberg), in: GRUR-Prax 06/2017, S. 267

BGH: Pflicht zur Angabe von Kontaktdaten des Herstellers durch Händler – Motivkontaktlinsen – Anm. zu BGH, Urt. v. 12.01.2017 – I ZR 258/15, in: GRUR-Prax 03/2017, S. 130 (gemeinsam mit Dr. Christian Stallberg)

Additional languages

English

Expertise

Sectors Life sciences & healthcare Pharmaceuticals Medical devices Biotech Cosmetics, food nutrition & supplements Digital health

Experience

Formycon

Under the leadership of the Frankfurt-based Taylor-Wessing partners Lars-Gerrit Lüßmann and Michael Sinhart, Formycon AG and ATHOS KG are merging their development activities in the field of so-called biosimilars, the follow-up products of biological medicines (biologics), in a long-term strategic partnership. The centrepiece of this agreement is Formycon AG’s participation in the rights of two biosimilars. The volume of the legally complex transaction (aggregate counter-performance) adds up to approximately 650 million euros.

Press release

Dr. Sebastian Beyer, LL.M. (Auckland)

Prof. Dr. Michael Johannes Pils

Marcus Hartmann

Dr. Andrea Sautter

Dr. Angela Knierim

See full team Hide full team

Awards